Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings

PRAX has already delivered a 685% return, meaning the risk/reward calculus is fundamentally asymmetric at current levels. The $80.5M capital injection provides a runway cushion but may also signal dilution risk depending on terms. Dual FDA filings bifurcate binary event risk, which statistically improves probability-weighted outcomes versus single-filing peers, but CNS drug development carries a historically elevated failure rate (~60-70% Phase II/III attrition). At this valuation multiple, the market has already capitalized significant optionality, leaving limited margin of safety against a rejection scenario which could trigger a 50-70% drawdown. ⚡ DEEP SONNET: Wait for 15-25% technical consolidation from current levels or identify a defined pre-PDUFA accumulation window (4-6 weeks prior to first FDA decision date). Ideal entry on high-volume retest of prior breakout level with confirmation of institutional accumulation patterns. | TP:28% SL:18% | 3-9 months aligned with FDA decision timelines | Risk:HIGH — Binary FDA outcomes on clinical-stage CNS asset with 685% embedded premium. CNS historically has among the highest late-stage failure rates in pharma. Dilution risk from $80.5M raise. Sector rotation out of high-multiple biotech remains a macro headwind in rate-sensitive environments. Position sizing must reflect extreme event-driven volatility. | Sizing:CONSERVATIVE